Arrowhead Pharmaceuticals (ARWR) Net Income (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Net Income of -$137.6 million for Q1 2026, down 587.12% on a QoQ basis from $28.2 million in Q4 2025, and down 137.4% year-over-year from $367.9 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Net Income (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Net Income history runs 17 years deep, the most recent figure standing at -$137.6 million for Q1 2026.
- Quarterly Net Income fell 137.4% year-over-year to -$137.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$271.9 million (down 75.8% YoY) and the FY2025 annual result came in at $30.1 million, up 104.94% from the prior year.
- Net Income was -$137.6 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $28.2 million in the prior quarter.
- Across five years, Net Income topped out at $367.9 million in Q1 2025 and bottomed at -$178.7 million in Q2 2025.
- A 5-year average of -$59.5 million and a median of -$104.1 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income tumbled 366.37% — and 2025, when it jumped 389.67%.
- Arrowhead Pharmaceuticals' Net Income stood at -$41.8 million in 2022, then slumped by 223.91% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025, then plunged by 587.12% to -$137.6 million in 2026.
- Business Quant data shows ARWR's Net Income at -$137.6 million in Q1 2026, $28.2 million in Q4 2025, and $16.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | -137.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.57 Mn |
| Dec 31, 2025 | 28.24 Mn |
| Sep 30, 2025 | 16.12 Mn |
| Jun 30, 2025 | -178.69 Mn |
| Mar 31, 2025 | 367.86 Mn |
| Dec 31, 2024 | -175.22 Mn |
| Sep 30, 2024 | -173.33 Mn |
| Jun 30, 2024 | -173.98 Mn |
| Mar 31, 2024 | -127.00 Mn |
| Dec 31, 2023 | -135.38 Mn |
| Sep 30, 2023 | -111.02 Mn |
| Jun 30, 2023 | -104.13 Mn |
| Mar 31, 2023 | 47.68 Mn |
| Dec 31, 2022 | -41.79 Mn |
| Sep 30, 2022 | -85.94 Mn |
| Jun 30, 2022 | -72.05 Mn |
| Mar 31, 2022 | 44.37 Mn |
| Dec 31, 2021 | -62.87 Mn |
| Sep 30, 2021 | -63.37 Mn |
| Jun 30, 2021 | -29.92 Mn |